Media, investors, advocacy organizations and others, please contact us here.

Downloadable Resources IgAN

PROTECT: Two-Year Efficacy and Safety Findings of Sparsentan

Learn more
Publications IgAN

Efficacy and Safety of Sparsentan Versus Irbesartan in Patients with IgA Nephopathy (PROTECT)

View
Publications FSGS

Sparsentan for Focal Segmental Glomerulosclerosis in the DUET Open-Label Extension: Long-term Efficacy and Safety

View
Publications IgAN

Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease

View
Publications IgAN

Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgA immune complexes in a mouse model of IgA nephropathy

View
Publications IgAN

Sparsentan: the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

View
Publications IgAN

Sparsentan, a Dual Endothelin Type A and Angiotensin II Subtype 1 Receptor Antagonist for the Treatment of Immunoglobulin A Nephropathy: Latest Trial Results, Pharmacokinetic Considerations, and Binding Profile

View
Publications FSGS

Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study

View
Publications

Physiologically-based pharmacokinetic model of sparsentan to evaluate drug-drug interaction potential

View
Publications IgAN

Sparsentan is superior to losartan in the gddY mouse model 1 of IgA nephropathy

View
Publications IgAN

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

View
Medical Information IgAN

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 PROTECT Study Published in The Lancet

Learn more
Medical Information FSGS

FILSPARI (sparsentan) – 2-Year Results from the Phase 3 DUPLEX Study Published in the NEJM

Learn more